



ACC.15

TCT@ACC-12 | innovation in intervention

A1482
JACC March 17, 2015
Volume 65, Issue 10S

Prevention

LOW LDL-CHOLESTEROL TARGET ACHIEVEMENT IN STATIN-TREATED PATIENTS IN CLINICAL PRACTICE IN CHINA AND EUROPE: RESULTS OF THE DYSLIPIDEMIA INTERNATIONAL STUDY (DYSIS)

Poster Contributions

Poster Hall B1

Sunday, March 15, 2015, 3:45 p.m.-4:30 p.m.

Session Title: Biomarkers, Hypertension and Lipid Management

Abstract Category: 21. Prevention: Clinical

Presentation Number: 1211-119

Authors: *Anselm K. Gitt, Baishali Ambegaonkar, Philippe Brudi, Martin Horack, Dominik Lautsch, DYSIS Study Group, Herzzentrum Ludwigshafen, Ludwigshafen, Germany, Institut f. Herzinfarktforschung Ludwigshafen, Ludwigshafen, Germany*

Background: Statin treatment is well established for patients with dyslipidemia and high risk for cardiovascular events. Little is known about differences in patient profile and LDL target achievement between Europe and China.

Methods: The cross sectional, observational study DYSIS examined lipid goal attainment among statin-treated very high cardiovascular risk patients (defined as per 2011 EAS/ESC guidelines, including patients with coronary heart disease, diabetes, chronic kidney disease or peripheral atherosclerotic disease) in Canada, Europe, Middle East and China. Data were collected 2008-2012 under real life conditions in physicians' offices and hospital outpatient wards. We compared the level of LDL-C goal achievement in Europe and China.

Results: A total of 25,317 patients were enrolled in China and 31,773 in Europe. Chinese patients less often were smokers and less often suffered from obesity, diabetes and hypertension, sedentary lifestyle, but more often had prior cerebro-vascular events. In both regions, two thirds of patients did not reach the recommended LDL-Chol target <70mg/dl. Chinese patients more often had combined dyslipidemia with low HDL-Chol as well as high triglycerides.

Conclusion: Patients treated with statins for secondary prevention in China have a substantially different cardiovascular risk profile as compared to European patients. Two thirds of patients in China and Europe do not reach the recommended LDL-Chol target value of <70mg/dl in clinical practice.

	China n= 25,317	Europe n= 31,773	p-value
Age (years)	65.8	65.5	<0.01
Female Gender	48.7 %	43.0 %	<0.01
BMI \geq 30 kg/m ²	5.5 %	34.9 %	<0.01
Hypertension	65.8 %	77.1%	<0.01
Diabetes mellitus	34.7 %	37.8 %	<0.01
Smoker (Current / former)	30.0 %	50.1 %	<0.01
Sedentary Lifestyle	19.7 %	50.0 %	<0.01
Cerebrovascular disease	16.9 %	9.9 %	<0.01
Statin = Simvastatin	41.3 %	43.4 %	<0.01
Statin = Atorvastatin	41.6 %	33.1 %	<0.01
Statin = Rosuvastatin	9.7 %	12.7 %	<0.01
LDL-Chol not at goal (<70mg/dl)	66.8 %	64.8 %	<0.01
Low HDL-Chol (<40mg/dl in men, <45mg/dl in women)	33.3 %	26.9 %	<0.01
TG > 150mg/dl	42.6 %	38.2 %	<0.01